Fidelity International’s Acadia Pharmaceuticals ACAD Stock Holding History

Fidelity International’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-126	Closed	-$6K	–	918
2020 Q2	$6K	Buy	+126	New	+$6.05K	﹤0.01%	751
2020 Q1	–	Sell	-112	Closed	-$5K	–	799
2019 Q4	$5K	Buy	+112	New	+$4.87K	﹤0.01%	774

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Fidelity International's ACAD Position: Q3 2020 in Review

Fidelity International sold out of Acadia Pharmaceuticals (ACAD) in Q3 2020, closing a stake of 126 shares — an estimated $6K sold.

Fidelity International first reported a position in ACAD in Q4 2019 and held it in 2 quarters. The position peaked at $6K in Q2 2020. 267 funds tracked by Wall St. Rank hold ACAD as of Q3 2020.

Fidelity International reported no remaining Acadia Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Fidelity International sold 126 Acadia Pharmaceuticals shares in Q3 2020, an estimated $6K.
Fidelity International first reported a position in Acadia Pharmaceuticals in Q4 2019 and held it in 2 quarters.
Fidelity International's Acadia Pharmaceuticals position peaked at $6K in Q2 2020.
267 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2020.

Based on Fidelity International's 13F filing for Q3 2020, filed 13 Nov 2020.